Bigul

SHILPA MEDICARE LTD. - 530549 - Ref: Regulation 30 Of The SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015; Scrip Code: BSE - 530549/ Stock Symbol: NSE - SHILPAMED

With reference to the captioned subject, Please be noted that pursuant to the Resolution passed at the meeting of the board of directors held on 10th November, 2020 at 11:30 A.M. the following items have taken on record. 1. The unaudited Financial Results (Standalone and Consolidated) for the quarter ended 31st December, 2019, pursuant to Regulation 33(3) of SEBI (LODR) Regulations, 2015. The Statement of Financial Results along with Statement of Assets and Liabilities, Cash Flow Statements and Limited review reports are enclosed as Annexure-1. It is further intimated that meeting commenced at 11:30 A.M. and concluded at This is for your information and necessary records.
10-02-2020
Bigul

SHILPA MEDICARE LTD. - 530549 - Sub: Intimation U/R 30 Of The SEBI(LODR) Regulations- Reg. Ref: Stock Code: NSE: SHILPAMED/BSE-530549

This is to inform you that USFDA (United States Food and Drug Administration) audit has been completed at our Active Pharmaceutical Ingredients (API) sites (Unit I and Unit_II) which are located at Raichur District, Karnataka between 3rd Feb, 2020 and 7th Feb, 2020. The Company is proud to announce that the USFDA reported with 'ZERO' observations. This is for your information and records.
08-02-2020

Top Gainers in the News: Shilpa Medicare, Ujjivan Financial Services, Swan Energy, Godrej Properties, Au Small Finance Bank

by Ritmbarah Arora Shilpa Medicare: The share price of Shilpa Medicare has soared 12.3% to 404.9 while around 5.8 lakh shares in volume have been traded so far. The share price gained 52.5% since the last week and 38.8% since the last month, per Trendlyne data. Shilpa Medicare received US Food and Drug Administration’s (USFDA) tentative approval for its ANDA, Pirfenidone tablets on February 3, 2020 post which the share price surged 6% in the morning trade hours. The company also received COSCO-New Delhi permission for manufacturing and marketing Lenvatinib capsules 4mg and 10 mg in India. Shilpa Medicare is listed in 23 screeners on Trendlyne. Ujjivan Financial Services: The share price of Ujjivan Financial Services gained 7.6% to Rs 411.7 as of now. Around 3.4 million shares in volume have been traded so far. The share price increased 10% since the last week and 19.3% since the last month. The share price of Ujjivan Financial Services started rising after the company announced net profit more than double in the December quarter results announced on February 3, 2020. Consolidated net profit jumped to Rs 74.9 crore in Q3FY20 as against Rs 31.8 crore in Q3FY19. Total income rose to Rs 764.7 crore from Rs 507.4 crore in the corresponding period of the previous financial year. Ujjivan Financial Services is listed in 22 screeners on Trendlyne. Swan Energy: Swan Energy’s share price jumped 14.2% to Rs 129.7. Around 1.7 lakh shares in volume have been traded today so far. The share price increased 12.1% since the last week and 4.8% since the last month. The company will conduct a Board of Directors meeting on Friday, February 14, 2020 to consider the unaudited financial results of the company for the quarter ended December 31, 2019. Swan Energy is listed in 14 screeners on Trendlyne. Godrej Properties: The share price of Godrej Properties advanced 7.6% to Rs 1,182 as of this writing. Around 6.9 lakh shares in volume have been traded so far. The share price of Godrej Properties is up 8.5% since the last week and 22.5% since the last month. Though, the company reported weak sales in the December quarter, the improvement in the cash flow was impressive. Operating cash flow increased to Rs 1,131 crore from Rs 900 crore in Q3FY19 which helped the company to trim the debt to Rs 1,093 crore from Rs 1,795 crore in the last year. Godrej Properties is listed in 20 screeners on Trendlyne. Au Small Finance Bank: The share price of Au Small Finance Bank rose 8.1% to Rs 1,136.6. Around 7.2 lakh shares in volume have been traded so far today. The share price gained 7.5% since the last week and 41% since the last month. Au Small Finance Bank reported net profit of Rs 190 crore in Q3FY20 which doubled from Rs 95.3 crore during the same period, previous year, as announced on January 23, 2020. Total income rose to Rs 1,272.8 crore from Rs 894.3 crore in Q3FY19 while total expenses increased to Rs 959.9 crore from Rs 715.6 crore in Q3FY19. Au Small Finance Bank is listed in 31 screeners on Trendlyne.
05-02-2020

Shilpa Medicare share price gains nearly 6% on USFDA nod

The company has received USFDA tentative approval for its ANDA Pirfenidone tablets.
03-02-2020
Bigul

Shilpa Medicare Ltd - 530549 - Intimation U/R 30 Of The SEBI(LODR) Regulations- Reg. Ref: Stock Code: NSE: SHILPAMED/BSE-530549

This is to inform you that the Company has received CDSCO -New Delhi Permission for manufacturing and marketing of Lenvatinib capsules 4mg and 10mg in India. Shilpa Medicare Limited is the first company to obtain Generic approval for Lenvatinib Capsules 4mg and 10mg in India. Lenvatinib capsules 4mg and 10mg is a generic equivalent of reference product, Lenvima, used in the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer and for the first line treatment of patients with unresectable hepatocellular carcinoma. According to IQVIA MAT Q2 2019 data, the Indian market for Lenvatinib capsules 4mg and 10mg is approximately US$ 0.32 million. This is for your information and doing the needful. With Regards,
31-01-2020
Bigul

Shilpa Medicare Ltd - 530549 - Intimation U/R 30 Of The SEBI(LODR) Regulations- Reg. Ref: Stock Code: NSE: SHILPAMED/BSE-530549

This is to inform you that the Company has received U.S Food and Drug Administration tentative approval for its ANDA, Pirfenidone Tablets, 267 mg and 801 mg on 30 Jan 2020. The ANDA is filed as 'First to File' submission on NCE -1 date. Pirfenidone Tablets, 267 mg and 801 mg is a generic equivalent of reference listed drug (RLD) Esbriet Tablets, 267 mg and 801 mg, of Hoffmann La Roche Inc. used in the treatment of idiopathic pulmonary fibrosis as recommended in the label approved by FDA. According to IQVIA MAT Q2 2019 data, the overall US market for Pirfenidone, 267 mg and 801 mg, strengths is approximately US$ 716.3 Million. This is for your information and doing the needful. With Regards,
31-01-2020
Bigul

SHILPA MEDICARE LTD. - 530549 - Board Meeting Intimation for Intimation Of Board Meeting Under Regulation 29 Of SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015. Ref.: Scrip Code: BSE: 530549 & NSE: SHILPAMED

SHILPA MEDICARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/02/2020 ,inter alia, to consider and approve With reference to the subject cited above, we wish to inform you that a meeting of the Board of Directors of Shilpa Medicare Limited will be held on Monday, the 10th day of February, 2020 to inter alia transact the following items of business: Approval of the unaudited Standalone and Consolidated financial results of the Company for the quarter ended 31st December, 2019. This is for your information and records. Thanking you,
27-01-2020
Bigul

Shilpa Medicare Ltd - 530549 - Shareholding for the Period Ended December 31, 2019

Shilpa Medicare Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2019. For more details, kindly Click here
11-01-2020
Bigul

SHILPA MEDICARE LTD. - 530549 - Statement Of Investor Complaints For The Quarter Ended December 2019

No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0110 Name of the Signatory :- V V KRISHNA CHAITANYADesignation :- Company Secretary and Compliance Officer
09-01-2020
Next Page
Close

Let's Open Free Demat Account